Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $23
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $16 to $23.
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $16 to $23.